Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Ardelyx, Inc. - Common Stock (NQ:ARDX)

6.740 +0.020 (+0.30%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ardelyx, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Present at the Jefferies 2023 Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/18
Via Investor Brand Network
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/13
Via Investor Brand Network
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/5
Via Investor Brand Network
News headline image
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
User Fee Goal Date: October 17, 2023 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/3
Via Investor Brand Network
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 3/30
Via Investor Brand Network
News headline image
Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
Company expects to receive goal review date in mid-May 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Publishes First Environmental, Social and Governance (ESG) Report
Report focuses on patient access and affordability, workforce wellness and training, community involvement and sound corporate governance 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Is Ardelyx is A Buy After Slip in Early 2022
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them 
Via MarketBeat
CapitalGainsReport Sector Spotlight: Healthcare Penny Stocks On The Move (ARDX, WHSI, BNGO)
Via AB Newswire
News headline image
Ardelyx, Inc. (NASDAQ:ARDX) Investor Alert: Investigation over Possible Breaches of Fiduciary Duties ↗
San Diego, CA -- (SBWIRE) -- 09/06/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Ardelyx, Inc. 
Via SBWire
News headline image
Ardelyx, Inc. (NASDAQ:ARDX) Long Term Investor Alert: Lawsuit Filed Against Directors ↗
San Diego, CA -- (SBWIRE) -- 06/03/2022 -- An investorsin shares of Ardelyx, Inc. (NASDAQ:ARDX) filed a lawsuit against certain directors of Ardelyx, Inc over alleged breaches of fiduciary duties. 
Via SBWire
News headline image
ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Ardelyx, Inc. (NASDAQ:ARDX) Long Term Shareholder Notice: Investigation of Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 10/28/2021 -- Certain directors of Ardelyx, Inc are under investigation over possible breaches of fiduciary duties. 
Via SBWire
Topics Lawsuit
News headline image
Kessler Topaz Meltzer & Check, LLP:  Important Deadline Reminder for Ardelyx Inc. Investors in Securities Fraud Class Action Lawsuit
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
News headline image
CLASS ACTION UPDATE for ARDX, ANVS and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / September 28, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.... 
From Levi & Korsinsky, LLP
Via AccessWire
Topics Lawsuit
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.